Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
11.18 USD | +0.68% | +7.07% | +70.99% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Sales forecast by analysts have been recently revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- Low profitability weakens the company.
- Based on current prices, the company has particularly high valuation levels.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+70.99% | 1.47B | B- | ||
-30.74% | 9.59B | A- | ||
-4.99% | 3.21B | C | ||
+27.61% | 2.92B | D+ | ||
-13.96% | 2.15B | - | B- | |
-16.43% | 1.79B | C+ | ||
+25.58% | 770M | C- | ||
-2.62% | 761M | C+ | ||
-25.61% | 548M | C- | ||
+4.97% | 316M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MRVI Stock
- Ratings Maravai LifeSciences Holdings, Inc.